Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Beckons: Sun Joins Indian Firms Priming For Larger Presence

Executive Summary

Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Advertisement

Related Content

Alembic Charts China Plans And Sees Price Cuts As No Dampener
Sandoz’ Unique Chinese Approval Paves The Way For Tender Access
Alembic Charts China Plans, Sees Price Cuts As No Dampener
Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List
Asia Deal Watch: Athenex Changes Mind, Gets Back Chinese Rights To Actinic Keratosis Candidate
Sun Firefights Governance Concerns
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
Cancer, Orphan, Pediatric Drug Developers Join China Foreign Data Acceptance Party
Is Sun wooing Lizhu for a larger presence in China?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

GB140301

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel